CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 375 filers reported holding CRISPR THERAPEUTICS AG in Q1 2023. The put-call ratio across all filers is 1.09 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,242 | -21.4% | 115,514 | -2.8% | 0.01% | -12.5% |
| Q2 2023 | $6,671 | +19.2% | 118,852 | -4.0% | 0.01% | +14.3% |
| Q1 2023 | $5,598 | +12.6% | 123,789 | +1.2% | 0.01% | 0.0% |
| Q4 2022 | $4,973 | -100.0% | 122,355 | -45.8% | 0.01% | -68.2% |
| Q3 2022 | $14,750,000 | -8.1% | 225,724 | -14.5% | 0.02% | 0.0% |
| Q2 2022 | $16,050,000 | +47.7% | 264,127 | +52.5% | 0.02% | +69.2% |
| Q1 2022 | $10,870,000 | +9.7% | 173,187 | +32.4% | 0.01% | +18.2% |
| Q4 2021 | $9,913,000 | +52.0% | 130,818 | +124.5% | 0.01% | +57.1% |
| Q3 2021 | $6,521,000 | -27.5% | 58,263 | +4.9% | 0.01% | -30.0% |
| Q2 2021 | $8,989,000 | +9462.8% | 55,529 | +7074.3% | 0.01% | – |
| Q1 2021 | $94,000 | -27.7% | 774 | -8.9% | 0.00% | – |
| Q4 2020 | $130,000 | +106.3% | 850 | -43.3% | 0.00% | – |
| Q1 2020 | $63,000 | – | 1,498 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |